ON THE ISSUE OF EXPANDING THE INDICATIONS OF THE USE OF AN IMMUNOMODULATING DRUG IN THE TREATMENT AND PREVENTION OF INFLUENZA AND ACUTE RESPIRATORY INFECTIONS IN YOUNG CHILDREN

ON THE ISSUE OF EXPANDING THE INDICATIONS OF THE USE OF AN IMMUNOMODULATING DRUG IN THE TREATMENT AND PREVENTION OF INFLUENZA AND ACUTE RESPIRATORY INFECTIONS IN YOUNG CHILDREN

The data on the safety and effectiveness of the use of the domestic immunomodulating preparation Polyoxidonium® (azoximer bromide) in children are summarized in the following pages. Polyoxidonium has an immunomodulatory (including interferon-inducing), detoxication and anti-inflammatory effect that...

Full description

Bibliographic Details
Main Author: V. F. Uchaikin
Format: Article
Language:Russian
Published: LLC "Diagnostics and Vaccines" 2017-09-01
Series:Detskie Infekcii (Moskva)
Subjects:
acute respiratory infections (ari)
azoximer bromide
polyoxidonium®
immunomodulator
children
Online Access:https://detinf.elpub.ru/jour/article/view/309
id doaj-d3bfde3c76cc4115947211e5ff95a73c
record_format Article
spelling doaj-d3bfde3c76cc4115947211e5ff95a73c2021-08-02T09:19:50ZrusLLC "Diagnostics and Vaccines"Detskie Infekcii (Moskva)2072-81072017-09-01163545810.22627/2072-8107-2017-16-3-54-58299ON THE ISSUE OF EXPANDING THE INDICATIONS OF THE USE OF AN IMMUNOMODULATING DRUG IN THE TREATMENT AND PREVENTION OF INFLUENZA AND ACUTE RESPIRATORY INFECTIONS IN YOUNG CHILDRENV. F. Uchaikin0Russian National Research Medical University named after N.I. Pirogov of the Ministry of Health of the Russian FederationThe data on the safety and effectiveness of the use of the domestic immunomodulating preparation Polyoxidonium® (azoximer bromide) in children are summarized in the following pages. Polyoxidonium has an immunomodulatory (including interferon-inducing), detoxication and anti-inflammatory effect that allows the clinical course of the disease to be quickly alleviated and the natural immune response modulated. The clinical effectiveness of the drug in acute respiratory infections (ARI) in children, including those with allergic anamnesis. Recent studies have proven the effectiveness of the 7-day course of the preparation Polyoxidonium® for the treatment and prevention of ARI and influenza in children, starting at the age of 3 years, as evidenced by a rapid positive dynamics of clinical symptoms and a 2-fold decrease in ARI frequency compared to placebo group at 6 months after the end of therapy.https://detinf.elpub.ru/jour/article/view/309acute respiratory infections (ari)azoximer bromidepolyoxidonium®immunomodulatorchildren
collection DOAJ
language Russian
format Article
sources DOAJ
author V. F. Uchaikin
spellingShingle V. F. Uchaikin
ON THE ISSUE OF EXPANDING THE INDICATIONS OF THE USE OF AN IMMUNOMODULATING DRUG IN THE TREATMENT AND PREVENTION OF INFLUENZA AND ACUTE RESPIRATORY INFECTIONS IN YOUNG CHILDREN
Detskie Infekcii (Moskva)
acute respiratory infections (ari)
azoximer bromide
polyoxidonium®
immunomodulator
children
author_facet V. F. Uchaikin
author_sort V. F. Uchaikin
title ON THE ISSUE OF EXPANDING THE INDICATIONS OF THE USE OF AN IMMUNOMODULATING DRUG IN THE TREATMENT AND PREVENTION OF INFLUENZA AND ACUTE RESPIRATORY INFECTIONS IN YOUNG CHILDREN
title_short ON THE ISSUE OF EXPANDING THE INDICATIONS OF THE USE OF AN IMMUNOMODULATING DRUG IN THE TREATMENT AND PREVENTION OF INFLUENZA AND ACUTE RESPIRATORY INFECTIONS IN YOUNG CHILDREN
title_full ON THE ISSUE OF EXPANDING THE INDICATIONS OF THE USE OF AN IMMUNOMODULATING DRUG IN THE TREATMENT AND PREVENTION OF INFLUENZA AND ACUTE RESPIRATORY INFECTIONS IN YOUNG CHILDREN
title_fullStr ON THE ISSUE OF EXPANDING THE INDICATIONS OF THE USE OF AN IMMUNOMODULATING DRUG IN THE TREATMENT AND PREVENTION OF INFLUENZA AND ACUTE RESPIRATORY INFECTIONS IN YOUNG CHILDREN
title_full_unstemmed ON THE ISSUE OF EXPANDING THE INDICATIONS OF THE USE OF AN IMMUNOMODULATING DRUG IN THE TREATMENT AND PREVENTION OF INFLUENZA AND ACUTE RESPIRATORY INFECTIONS IN YOUNG CHILDREN
title_sort on the issue of expanding the indications of the use of an immunomodulating drug in the treatment and prevention of influenza and acute respiratory infections in young children
publisher LLC "Diagnostics and Vaccines"
series Detskie Infekcii (Moskva)
issn 2072-8107
publishDate 2017-09-01
description The data on the safety and effectiveness of the use of the domestic immunomodulating preparation Polyoxidonium® (azoximer bromide) in children are summarized in the following pages. Polyoxidonium has an immunomodulatory (including interferon-inducing), detoxication and anti-inflammatory effect that allows the clinical course of the disease to be quickly alleviated and the natural immune response modulated. The clinical effectiveness of the drug in acute respiratory infections (ARI) in children, including those with allergic anamnesis. Recent studies have proven the effectiveness of the 7-day course of the preparation Polyoxidonium® for the treatment and prevention of ARI and influenza in children, starting at the age of 3 years, as evidenced by a rapid positive dynamics of clinical symptoms and a 2-fold decrease in ARI frequency compared to placebo group at 6 months after the end of therapy.
topic acute respiratory infections (ari)
azoximer bromide
polyoxidonium®
immunomodulator
children
url https://detinf.elpub.ru/jour/article/view/309
work_keys_str_mv AT vfuchaikin ontheissueofexpandingtheindicationsoftheuseofanimmunomodulatingdruginthetreatmentandpreventionofinfluenzaandacuterespiratoryinfectionsinyoungchildren
_version_ 1721235141110530048

Similar Items